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Cardiovascular disease continues to be the most important global health challenge 
causing one third of mortality world-wide. A great proportion of cardiovascular deaths 
falls in the category of coronary artery disease (CAD) as a result of myocardial infarction. 
This catastrophic event in many cases occurs as the first sign of cardiovascular disease 
when it is too late for preventive strategies. It is thus particularly important to be able to 
understand mechanisms involved in cardiovascular disease and to predict an event 
preferably years before it occurs to allow time for risk modification.  
The biological pathology underlying cardiovascular disease is atherosclerosis. In CAD, 
atherosclerosis occurs within the coronary arteries. The endothelial surface of the 
atherosclerotic plaque could lose integrity and rupture. Consequent coagulation cascade 
forms thrombus inside coronary artery and blocks it at which point myocardial infarction 
is inevitable. Coagulation factors and platelet functioning are pivotal in formation of 
thrombus. Currently aspirin is a commonly used as antiplatelet therapy [1] in patients 
with cardiovascular disease or those carrying high risk of cardiovascular disease. Aspirin 
has however side effects such as risk of bleeding which is a risk that is widely accepted 
since preventive impact of aspirin outweighs the risk of bleeding. 
It is for long known that ABO blood group antigens are present at the surface of platelets 
[2] and for nearly half a century, a link between ABO blood group antigens and 
cardiovascular disease was known [3]. ABO blood group is associated with many traits in 
addition to cardiovascular disease including platelet function parameters among healthy 
adults and patients with CAD [4, 5].  
Upon advent of agnostic statistical approaches such as genome-wide association studies 
(GWAS), new insight into mechanism of cardiovascular disease at molecular level started 
to emerge. In recent years, GWAS showed that ABO genetic locus that encodes for ABO 
blood group antigens has a highly pleiotropic nature and is strongly associated with many 
traits including coagulation factors, adhesion molecules and cardiovascular disease 
(Figure 1). Understanding biological interaction between the ABO locus and molecules 
involved in clot formation is fundamental. It provides insight that could potentially lead 
to production of new drugs to boost prevention of cardiovascular events. 
In this issue of the journal, Christiansen and colleagues investigated the role of 45 CAD 
genetic variants on platelet activation and aggregation. They used a sample of 879 
patients with CAD under aspirin therapy. Patients who used medication with potential 
effect on coagulation were excluded. However, most of the patients used aspirin and as 
the authors pointed out some could be under aspirin treatment long before entering the 
study. The results showed that except for the ABO CAD risk variants, none of the CAD 
variants were linked to platelet aggregation and activation. The study showed that 
measures of platelet aggregation (arachidonic acid, and collagen) were higher and sP-
selectin levels was lower among carriers of ABO risk allele compared to non-carriers.  
GWAS on general population indicate that the ABO locus is strongly associated with 
serum levels of adhesion molecules such as sP-selectin [6-10]. Additional to the findings 
of the GWAS, Christiansen and colleagues highlight differences in arachidonic acid, 
collagen, and sP-selectin depending on the ABO CAD genotypes among CAD patients who 
are under aspirin treatment.  
As mentioned earlier, ABO locus is associated with CAD and several cardiovascular risk 
factors such as lipid levels and type1 diabetes. Thus, compared with non-carriers, carriers 
of ABO CAD risk allele are more likely to have had CAD risk factors prior to entering the 
study. Prescription of aspirin as a preventive method in CAD in many countries means 
that individuals at high risk of CAD (i.e. those with CAD risk factors) have a greater chance 
to receive aspirin. This means carriers of ABO CAD risk allele are more likely to have been 
under aspirin therapy well in advance of the time that measurement of platelet function 
was taken by Christiansen and colleagues. As a result of longer duration of aspirin therapy 
in carriers, their platelet functioning parameters decrease disproportional to the ones of 
non-carriers. Such effect might lead to underestimation of the finding with a magnitude 
that depends on the effect of long-term aspirin use on platelet function. This could be 
further complicated as aspirin response is not similar in all individuals. It is important for 
future research to ensure that aspirin response is independent of ABO locus which 
necessitates collecting data before and after aspirin use.  
Christiansen and colleagues present interesting results, showing yet another evidence for 
the impact of ABO locus on platelet functioning parameters. It is however unclear how 
the finding would be different before and after aspirin therapy and if these findings are 
different from the results among healthy controls who use aspirin for reasons other than 
CAD or those who do not use aspirin at all. Follow-up research is essential to demonstrate 
how the results observed here are linked to CAD and response to aspirin therapy in 
longitudinal studies. 
It is yet too soon to believe that the findings of Christiansen and colleagues explain the 
greater chance of myocardial infarction among carriers of ABO CAD risk allele. Given the 
highly pleiotropic nature of ABO locus and presence of the ABO blood group antigens on 
many various cell types, it is more likely that ABO locus involves in multiple pathways 
leading to myocardial infarction.  
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Figure 1. Schematic illustration of pleiotropy in ABO locus.  
  
 
 
